For research use only. Not for therapeutic Use.
LY2880070 is an orally active CHK1 inhibitor. LY2880070 can be used as an anticancer agent for combination with DNA damaging agents[1].
| Catalog Number | I040618 |
| CAS Number | 1375637-35-6 |
| Synonyms | N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine |
| Molecular Formula | C19H23N7O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23N7O2/c1-12-5-6-14(19(22-12)27-2)15-8-16(26-25-15)23-17-10-21-11-18(24-17)28-13-4-3-7-20-9-13/h5-6,8,10-11,13,20H,3-4,7,9H2,1-2H3,(H2,23,24,25,26)/t13-/m1/s1 |
| InChIKey | LAEFIEWPUJMANC-CYBMUJFWSA-N |
| SMILES | CC1=NC(=C(C=C1)C2=CC(=NN2)NC3=CN=CC(=N3)OC4CCCNC4)OC |
| Reference | [1]. Quincy S, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 2020 38:15_suppl, 3581. |
